Article | November 16, 2022

Embrace Innovation To Dodge Rising Trial Costs

Source: Pro-ficiency

By David Hadden, President and Founder of Pro-ficiency


The cost of conducting a clinical trial has been rising in recent years and that trend shows no signs of abating anytime soon. And that means that the clinical research industry needs to overcome its traditional resistance to change and adopt innovations that can save both money and time to mitigate the impact of those rising costs.

But it’s not enough to merely adopt new technologies or other innovative practices and hope that costs go down. It is important to carefully select the innovations adopted based on four tests:

  • Does it reduce cost and/or time?
  • Does it cause creative destruction, or replacement of old processes with improved ones?
  • Does it require doing business differently, in a better, more efficient way?
  • Do users love it and actually use it?

The cost of everything is rising rapidly, and the cost of developing new pharmaceuticals is no exception. Increases in areas like food, gas and airfare play a role in the increased cost of pharma R&D, but clinical trials also face unique factors that add to their expense. According to 2021 estimates by Deloitte, the average cost of development has soared from $450 million in 2013 to $2.45 billion in 2020.[1] 

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader